Cheng, Y., He, Y., Li, W., Zhang, H., Zhou, Q., Wang, B., . . . Ramalingam, S. S. (2021). Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study. Target Oncol.
Citação norma ChicagoCheng, Ying, et al. "Osimertinib Versus Comparator EGFR TKI As First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study." Target Oncol 2021.
Citação norma MLACheng, Ying, et al. "Osimertinib Versus Comparator EGFR TKI As First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study." Target Oncol 2021.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.